NunaBio

Based in the United Kingdom, NunaBio is a startup founded in 2012. Its most recent tracked round is Seed. Brouky classifies it under Healthcare & Life Sciences. Brouky records 1 investor associated with the company.

NunaBio provides a next-generation cell-free enzymatic platform for the synthesis, assembly, and amplification of high-fidelity synthetic DNA at gram scale within days, targeting biotech, pharma, and government partners with multiple DNA formats and distributed micro-foundry deployment.